Subjects and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
http://www.who.int/hiv/mediacenter/200605-FS_globalfactsfigures_en.pdf. accessed July 6, 2006.
- The effectiveness of condoms in reducing heterosexual transmission of HIV.Fam Plann Perspect. 1999; 31: 272-279
- Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina.Lancet. 1997; 350: 922-927
- The effect of hormonal contraception on genital tract shedding of HIV-1.AIDS. 2004; 18: 205-209
- How estrogen or progesterone might change a woman's susceptibility to HIV-1 infection.Aust N Z J Obstet Gynaecol. 2002; 42: 472-475
- Contraceptive choice for HIV positive women.Sex Transm Infect. 2004; 80: 167-173
- Is the intrauterine device appropriate contraception for HIV-1-infected women?.BJOG. 2001; 108: 784-790
- A comparison of flubriprofen, tranexamic acid and a levonorgestrel-releasing intrauterine device in the treatment of idiopathic menorrhagia.Am J Obstet Gynecol. 1991; 164: 879-883
- Ovarian function during the use of levonorgestrel-releasing IUD.Contraception. 1990; 42: 51-66
- Protective effect of intrauterine release of levonorgestrel on pelvic infections: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices.Obstet Gynecol. 1991; 77: 261-264
- Guillebaud J. Contraception ��� your questions answered. 4th ed. Churchill Livingstone, London2004: 406-407
- Successful use of levonorgestrel intrauterine system in a HIV positive woman.Br J Fam Plann. 1999; 25: 25-26
- Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up.JAMA. 2004; 291: 1456-1463
- Complications after caesarean section in HIV-1-infected women not taking antiretroviral treatment.Lancet. 1999; 354: 1612-1613
- Risk of invasive cervix cancer among women with, or at risk for, HIV-infection.Int J Cancer. 1999; 82: 334-337
- Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections.J Infect Dis. 2003; 188: 555-563
Lehtovirta P, Finne P, Nieminen P, et al. Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women ��� a long-term follow-up study in a low prevalence population. Int J STD AIDS 2006 [in press].
- Effect of intrauterine device use on cervical shedding of HIV-1 DNA.AIDS. 1999; 13: 2091-2097
Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women ��� effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006 [in press].
���Financial support from the University Central Hospital Research Funds is gratefully acknowledged. Dr. Heikinheimo is the recipient of a Finnish Medical Foundation Clinical Fellowship grant.
������The contents of the present manuscript do not necessarily reflect the policy of the funding sources.